Ampronix Inc. announced that it will feature a wide variety of medical imaging products at the Radiological Society of North America (RSNA) 2015 annual meeting.
CIRS ATOM phantoms are a full line of anthropomorphic, cross sectional dosimetry phantoms designed to investigate organ dose, whole body effective dose as well as verification of delivery of therapeutic radiation doses.
ATOM is the only line of dosimetry phantoms to range in sizes from newborn to adult. Six models are available: newborn, 1-year, 5-year and 10-year old pediatric phantoms as well as adult male and female phantoms.
Samsung NeuroLogica Corporation, the healthcare subsidiary of Samsung Electronics Co., Ltd. and a leading provider of advanced imaging solutions, announced today that the University of Wisconsin (UW) Carbone Cancer Center in Madison acquired and is incorporating NeuroLogica’s BodyTom technology into its radiation oncology brachytherapy planning process.
Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer – from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing.
RaySearch Laboratories AB (publ) announced today that The US Oncology Network, one of America’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care, has selected RayStation to be offered throughout The US Oncology Network as one of the available radiation therapy treatment planning systems.
IBA (Ion Beam Applications S.A.) announced that the newly opened Texas Center for Proton Therapy is now treating cancer patients, using image-guided Pencil Beam Scanning (PBS).
In a paper published in the journal Nature Communications, University of California, San Diego School of Medicine researchers identified a pathway that causes the resistance and a new therapeutic drug that targets this pathway.
Low-risk prostate cancer patients in Canada may be opting for treatment with major life-changing side-effects without fully understanding other options, including the choice to forego treatment unless the disease progresses, a new report reveals.
During the eighties and nineties — the heydays of radiology — sexism abounded on the RSNA exhibit floor. Gone today are the women who were stationed strategically along the periphery of vendor booths, hired from Chicago modeling agencies, instructed to reel in the heavily male prospects then hand them off to sales people. Gone also are the spandex-clad models who once adorned the X-ray and magnetic resonance imaging (MRI) tables. The women in mammography videos are older than 22.
